• Publications
  • Influence
Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool.
TLDR
In a preliminary study, among patients prescribed opioids for chronic pain, the ORT exhibited a high degree of sensitivity and specificity for determining which individuals are at risk for opioid-related, aberrant behaviors. Expand
Naloxegol for opioid-induced constipation in patients with noncancer pain.
TLDR
Treating naloxegol, an oral, peripherally acting, μ-opioid receptor antagonist, for the treatment of opioid-induced constipation resulted in a significantly higher rate of treatment response, without reducing opioid-mediated analgesia. Expand
A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
TLDR
Slow titration of ziconotide, a nonopioid analgesic, to a low maximum dose resulted in significant improvement in pain and was better tolerated than in two previous controlled trials that used a faster titration to a higher mean dose. Expand
Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid‐induced constipation
TLDR
The mechanism of opioid‐induced constipation differs from that of functional constipation (FC), and OIC may not respond as well to most first‐line treatments for FC. Expand
Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base.
TLDR
This guideline offers a strategic approach to creating a comprehensive evidence base to guide safe and effective management of CNCP and offered 4 recommendations in 3 areas. Expand
A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation
TLDR
It is demonstrated that once‐daily oral naloxegol improves the frequency of SBMs compared with placebo and is generally well tolerated in this population of patients with OIC. Expand
Sleep-disordered breathing and chronic opioid therapy.
TLDR
The dose-response relation of sleep apnea to methadone and benzodiazepines calls for increased vigilance. Expand
Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain.
TLDR
Oxytrex is the first large well controlled study to show strong analgesia with minimal withdrawal symptoms and better safety compared with oxycodone, and preclinical data also show a suppression of opioid tolerance and dependence. Expand
Randomised clinical trial: the long‐term safety and tolerability of naloxegol in patients with pain and opioid‐induced constipation
TLDR
Opioid‐induced constipation (OIC) is a common adverse effect of opioid therapy and should not be considered a cause for concern in patients receiving opioid therapy. Expand
Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic
TLDR
Although treatment appeared to be safe and well tolerated, a single 60-minute application of NGX-4010 failed to show efficacy in this study which included patients with PHN for less than 6 months. Expand
...
1
2
3
4
5
...